Systematic review of the efficacy, effectiveness and safety of MF59 adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age
This review aimed to assess the efficacy, effectiveness and safety of MF59® adjuvanted trivalent and quadrivalent influenza vaccines to prevent laboratory-confirmed influenza.
This Academic Publication is available from
Date of publication:
10 Feb 2022
Authors:
Eamon O Murchu, Laura Comber, Karen Jordan, Sarah Hawkshaw, Liam Marshall, Michelle O'Neill, Conor Teljeur, Máirín Ryan, AnnaSara Carnahan, Jaime Jesús Pérez Martín, Anna Hayman Robertson, Kari Johansen, Jorgen de Jonge, Tyra Krause, Nathalie Nicolay, Hanna Nohynek, Ioanna Pavlopoulou, Richard Pebody, Pasi Penttinen, Marta Soler-Soneira, Ole Wichmann, Patricia Harrington
Journal:
Reviews in Medical Virology
Digital object identifier:
DOI: 10.1002/rmv.2329
Type of output:
Evidence synthesis
Suggested Citation:
O Murchu E, Comber L, Jordan K, Hawkshaw S, Marshall L, O’Neill M, Teljeur C, Ryan M, Carnahan A, Pérez Martín JJ, Hayman Robertson A, Johansen K, de Jonge J, Krause T, Nicolay N, Nohynek H, Pavlopoulou I, Pebody R, Penttinen P, Soler-Soneira M, Wichmann O & Harrington P. Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology. 2022;e2329.